FDA Clearance Tracker · P250011
ProVee System for BPH
Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Dec 9, 2025
Approved
Time to decision
251 days
Received Apr 2, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250011
- Device name
- ProVee System for BPH
- Applicant
- Proverum, Ltd.
- Applicant location
- Dublin
- Received
- Apr 2, 2025
- Decided
- Dec 9, 2025
- Decision
- Approved
- Supplements
- 6 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- GI, Urology & NephrologyUrology
FDA's approval statement
As written in FDA's record.
The ProVee System for BPH is intended for the treatment of obstructive lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH) in men with prostatic urethral lengths greater than or equal to 3.75 cm and prostatic volumes between 30 and 80 cc.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MER. The earliest in FDA's data is P920023-S002, decided Sep 27, 1996.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Proverum, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.